OPRX OptimizeRx Corporation

OPTIMIZERx Corporation (PINKSHEETS: OPRX) announced today that it has completed a $3.5 million corporate financing transaction to further support its growth plans of www.OPTIMIZERx.com and to accelerate the rollout of its marketing platforms, including the recently introduced OFFERx(TM) and the soon to be launched ADHERxE(TM) platforms.

The transaction was completed between the Company and the Vicis Capital Master Fund. The financing was placed by Midtown Partners & Co., LLC (www.midtownpartners.com), a FINRA member & SIPC Broker/Dealer.

OFFERx(TM) provides a single, turn-key platform to allow more pharmaceutical and healthcare companies to develop, test and expand superior patient savings and support programs on a faster and more cost-effective basis.

The company's upcoming launch of ADHERxE(TM) will also provide turn-key solutions to address the pharmaceutical industry's number one challenge: helping patients stay on their medicines longer.

The ADHERxE(TM) platform will soon allow leading Rx brands to turn their patient offers into powerful compliance programs that include surveying patient results each month in exchange for re-activation of their co-pay card. This program allows the brand to regularly engage the patient and helps minimize any barriers on maintaining treatments for important chronic therapies.

"We are very excited that we have completed this financing transaction and now can put our full efforts into the growth of our three solution platforms to help our clients improve patient awareness, access and adherence. I look forward to seeing the impact that our product line up will have in supporting our clients growth, as well as in helping more patients better afford and stay on their medications," says David Harrell, CEO of OPTIMIZERx.

About OPTIMIZERx Corporation

OPTIMIZERx provides unique platforms to help patients better afford and comply to their medicines and healthcare products, while offering pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company's web-based consumer information and patient support website, www.OPTIMIZERx.com, and its permanent subscriber base, continues to grow each month and is quickly becoming the preferred way to access branded prescription savings and support programs. Additionally, OPTIMIZERx has integrated and developed peripheral offerings and capabilities, most obviously the newly launched OFFERx(TM) offer management system to allow more brands to participate in promoting a new trial or co-pay program, as well as sophisticated online behavioural re-targeting and database marketing of brand-name pharmaceuticals, OTC medications, medical devices, and healthcare services that provide OPTIMIZERx visitors and subscribers the highest possible value and the best possible medical outcome for their specific condition.

'SAFE HARBOR'

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact: Investor Relations First Capital Investors, Inc. www.firstcapitalinvestors.com Email Contact 321-221-2910